Home    eJManager.com Add Your Journal   |    Follow on Twitter   |    Subscribe to List

Directory for Medical Articles
 

Open Access

-



Telaprevir combination therapy in patients infected with hepatitis C virus genotype 4

Bilgehan Aygen; Orhan Yýldýz; Selma Gökahmetoðlu; Serpil Taheri; Zeynep Türe.

Abstract
Introduction: The sustained virological response (SVR) rate for genotype 4 (G4) HCV-infected patients after pegylated interferon (PegIFN) and ribavirin (RBV) treatment is approximately 60%. We aimed to investigate the efficacy and safety of telaprevir (TVR) in combination with PegIFN and RBV in patients infected with G4 HCV who were previously treated with PegIFN/RBV and failed to achieve SVR.
Material and Methods: The study included 10 patients: two prior relapsers, two prior partial responders, and six prior null responders to PegIFN/RBV treatment. The patients were given TVR/PegIFN/RBV for 12 weeks, followed by a 12-36 weeks PegIFN/RBV treatment. Rapid virological response (RVR), early virological response (EVR), extended rapid virological response (eRVR), SVR, and side effects of therapy were evaluated.
Results: The mean age of the patients was 48.90±12.52 years and seven were female. All of HCV isolates were typed as 4d. Interleukin (IL) 28B genotype was found CT in seven patients and two patients had cirrhosis. Treatment was stopped within four weeks because of the side effects in two patients. Three of the remaining eight patients (37.5%) achived HVR, RVR, and eHVR. SVR was obtained in two of these patients, but one patient relapsed. SVR rates were 25% in all patients.
Conclusion: TVR combination therapy had limited antiviral activity in this patient population. Further investigation of TVR combination therapy in patients with HCV G4 infection is warranted.

Key words: Hepatitis C virus;Genotype 4;Chronic hepatitis C;Telaprevir;Treatment-experienced


Full text links

Share this Article




ScopeMed Home
Follow ScopeMed on Twitter
Article Tools
Job Opportunities/Service Offers
eJManager OJMS
eJPort Journal Hosting
About ScopeMed
Terms & Conditions
Privacy Policy
Suggest a Journal
Publisher Login
Contact Us

The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Service of eJManager LLC Publishing for Scientific Publications. Copyright © ScopeMedź Information Services.
Scopemed Buttons